Perspective Therapeutics CATX
NYSE CATX
$2.83 -0.16 (-5.52%)
As of: Sep 10, 2026 · 11:58 AM EDT

Perspective Therapeutics (CATX) Inventory Average (2011 - 2023)

Perspective Therapeutics' (CATX) quarterly Inventory Average came in at $1.1 million in Q3 2023, down 28.55% year-over-year from $1.5 million in Q3 2022, and down 15.79% quarter-over-quarter from $1.3 million in Q2 2023.

Analysis

Perspective Therapeutics (CATX) Inventory Average (2011 - 2023) Analysis & Trends

Perspective Therapeutics has disclosed Inventory Average across 12 years of filings, most recently posting $1.1 million for Q3 2023.

  • In Q3 2023, Inventory Average fell 28.55% year-over-year to $1.1 million; the TTM figure through Sep 2023 stood at $1.1 million (down 28.55% YoY), while the FY2022 annual figure was $1.4 million, changed N/A from the prior year.
  • Inventory Average came in at $1.1 million for Q3 2023 at Perspective Therapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $1.5 million in Q4 2022 to a low of $513500.0 in Q1 2019.
  • Average Inventory Average over 5 years is $908184.2, with a median of $855500.0 recorded in 2021.
  • Year-over-year, Inventory Average surged 62.94% in 2021 and slipped 28.55% in 2023.
  • Over 5 years, Inventory Average stood at $523000.0 in 2019, then grew by 24.86% to $653000.0 in 2020, then surged by 62.94% to $1.1 million in 2021, then surged by 39.19% to $1.5 million in 2022, then slipped by 28.87% to $1.1 million in 2023.
  • Per Business Quant data, the three most recent Inventory Average figures were $1.1 million in Q3 2023, $1.3 million in Q2 2023, and $1.4 million in Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inventory Avg. (Qtr)
1 Amgen 207.09 Bn 193.10 Bn 7.24 Bn 6.20 Bn
2 Gilead Sciences 179.68 Bn 176.50 Bn 6.22 Bn 1.93 Bn
3 Vertex Pharmaceuticals 131.39 Bn 123.54 Bn 2.84 Bn 1.77 Bn
4 Regeneron Pharmaceuticals 81.79 Bn 73.79 Bn 3.93 Bn 3.09 Bn
5 Argenx Se 61.15 Bn 55.97 Bn 1.37 Bn -
6 Moderna 53.35 Bn 48.21 Bn 52.00 Mn 213.00 Mn
7 Alnylam Pharmaceuticals 33.40 Bn 30.10 Bn 992.69 Mn 90.57 Mn
8 Biogen 31.66 Bn 30.38 Bn 1.96 Bn 2.17 Bn
9 Roivant Sciences 29.14 Bn 29.14 Bn 1.16 Mn -
10 Perspective Therapeutics 340.24 Mn 340.24 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 1.05 Mn
Jun 30, 2023 1.25 Mn
Mar 31, 2023 1.41 Mn
Dec 31, 2022 1.48 Mn
Sep 30, 2022 1.47 Mn
Jun 30, 2022 1.28 Mn
Mar 31, 2022 1.12 Mn
Dec 31, 2021 1.06 Mn
Sep 30, 2021 1.02 Mn
Jun 30, 2021 855,500.00
Mar 31, 2021 698,000.00
Dec 31, 2020 653,000.00
Sep 30, 2020 643,000.00
Jun 30, 2020 612,500.00
Mar 31, 2020 562,500.00
Dec 31, 2019 523,000.00
Sep 30, 2019 515,500.00
Jun 30, 2019 531,500.00
Mar 31, 2019 513,500.00
Dec 31, 2018 490,500.00